Return to Faculty List


Bhaskar Das

Professor of Pharmaceutical Sciences

Ph.D. Organic SynthesisM.Phil. Organic SynthesisM.S. Organic Synthesis


In 19 years of research experience, Dr. Das has published 25 patents, 80 peer reviewed papers, 20 papers are under preparation, many abstracts and 5 book chapters. Five technologies have transferred to pharmaceutical industries (currently in preclinical trials). Two drugs have been FDA approved. Dr. Das has trained 20 postdocs, 5 Ph.D students, 30 Undergraduate students and 25 high school students. His laboratory is the first in the world explored the boron based small molecules as potential therapeutic and diagnostic agents in an academic setting.

Overall, Dr. Das focuses on Boron based small molecules design and synthesis and the use these compounds as potential therapeutic and diagnostic agents for different diseases areas. These new reactions are used globally to synthesize different organic compounds and new compounds are utilized as potential therapeutic and diagnostic agents for different diseases areas.


New methodologies for carbon-boron bond formation to synthesize boron-containing unnatural amino acids for use in cancer therapy.  Synthesis of chemical libraries of boron-containing agents for use in the treatment of brain cancer and neurodegenerative diseases.  Development of chemical libraries of PET and SPECT imaging agents for non-invasive diagnoses of Alzheimer's disease and brain cancer.  Development of new therapeutic and diagnostic agents for brain cancer, prostate cancer, obesity and cardiovascular diseases. 



Total 28 # (25 reported, 3 under preparation)

Elmaleh, D.R., Das, B.C.; Shoup,T., Fischman, A.J. Specific aryl bidentate isonitriles and their uses. (2007). US Patent Application # 60/793,032 (2007). PCT Int. Appl. 2007. WO 2007123934. (Technology transfer to Fluoropharma Company).

Mani, S., Das, B.C. Ketoconazole derivative antagonist of human preganane X receptors. (2008). International Patent Application No.PCT/US2009/000524, PCT Publication No. WO 2009/110955A2.

Kalpana, G.V., Das, B.C. Fenretinamide derivatives and uses thereof as therapeutic, diagnostic and imaging agents. (2009). PCT International Patent Application No. PCT/US2009/001538, PCT Publication No. WO 2009/114136A2

Das, B.C., Mani, S.. Hypoxia Targeted Compounds for Cancer Diagnosis and Therapy. (2010). PCT International Patent Application No. PCT/US2009/006170, PCT Int. Appl. (2010), WO 2010068238 A1 20100617

Jubinsky, P., Das, B.C., and Short, M.K. Mitochondrial Inhibitors to treat human disease. (2010). PCT International Patent Application No. PCT/US2010/000787, PCT Int. Appl. WO 2010120337 A1 20101021

Das, B.C., Yang, F., Zhao, X., Pessin, J.E., Zong, H., and Ji, Y-U. Novel lipogenic inhibitors and uses thereof. (2011). U.S Patent Application No. 61/443,426. 2011, WO 2012112670, A1 2012082

Pessin, J.E., Yamada, E., Das, B.C., Bastie, C. C. (2010). Novel regulators of FYN-LKB1 interaction and uses thereof. U.S. Provisional Application No. 61/450,925.

Dhurandhar, N., Das, B.C. Compositions and methods for Improving Glucose uptake. (2012). U.S. Patent Application No. 61/714,899. PCT Int. Publication No. WO2014/062794A1. (Technology transfer to Vital Health, Inc. Company).

Bhsakar C. Das.; Nikhil V. Dhurandhar. Small Molecule Analogs of E4ORF1. (2014) PCT No.: PCT/US2015/026779.; Publication.No: US2017/0037064A1.

Das, B. C., Evans, T. Boron containing oxadiazole based retinois as novel therapeutic and diagnostic agents for neurological diseases. (2013). U.S. Patent. Application No. 61/661, 546.

Wallace, D.P., Das, B.C. Novel LKB1 activator for the therapeutic use in Polycystic Kidney disease. (2013). U.S. Patent. Application No (61/901,324). US2017/03348921-A1

Cuervo, A.M., Das, B.C.,Gavathiotis, E ., Xin; Qisheng. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof. 2016, No.US9512092B2, WO2012139080A. (Technology transfer to Selphagy Company).

Das, B. C., Weiss, LM. Boron containing MetAP2 (Methionine Aminopeptidase-2) inhibitors for therapeutic applications. (2019). Submitted to AECOM.

Das, B.C., Wallace, D.P. Boron-based Integrin-Linked Kinase (ILK) inhibitors for therapeutic and diagnostic uses. (2018). Submitted to KUMC.

Bhaskar C. Das, Todd Evans. Design and Synthesis of Boron Containing Novel Biologically Specific Retinoids and their Uses. Submitted. 2017, Weill Cornell Medical College NY. CCTEC-D5914.

John Cijiang HE, Ruijie LIU, Bhaskar Das, Wenzhen Xiao, Zhengzhe Li, and Kyung Lee. OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS.PCT/US2018/012512) (Technology Transferred to Shanghai Pharma).

Bhaskar C. Das, Mridul Mukherjee. NOVEL BORON-CONTAINING COMPOUNDS AND METHODS OF USE. USA. 2016. U.S. Application No. 62/589,031.

Yifei Zhong., John Cijiang He., Bhaskar Das., Ruijie Liu., Honggang Gu. Method of Preparing ATG’s Analogue, and the Application of ATG and it’s analogue. US2017/0313667.

Bhaskar C. Das, Daniela Bota. Development of Lon Protease inhibitors. Submitted to UC Irvine, USA. December 10, 2017.

Barbara Murphy., Bhaskar C. Das., Chengguang Wei. HCK Inhibitors for the treatment of fibrosis and cancer. Provisional Patent Application Serial #: 62/828,143, filed April 2019. (Technology transfer to EVOTEC Company).

Bhaskar C. Das, Sandeep Mallipattu. Small molecule KLF15 agonist BT412 for Kidney Diseases. Submitted, 2019, USA- IPR 19 008.

Bhaskar C. Das, Louis Weiss, Nikhil Dhurandhar, and Vijay Hegde. A MetAP2 inhibitor blocks adipogenesis, yet improves glucose uptake. 2019/PCT/62/865,059.


Cuervo, A.M., Das, B.C., Gavathiotis, E., Xin; Qisheng. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof. 2019/ US 10,189,827.